Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Insulin glargine U300 in uncontrolled type 2 diabetes mellitus
NCT05002933Phase 4Completed
- Sponsor
- Sanofi
- Start
- May 2021
- Primary completion
- Feb 2023
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 4 trial of insulin glargine U300 in type 2 diabetes mellitus (T2DM), sponsored by Sanofi. Started May 2021; status: completed.
02
Drugs
insulin glargine U300
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05002933.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05002933.